AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 in patients with
CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.